Roche to acquire 89bio in a $3.5bn deal.

Roche, a global healthcare company operating in the pharmaceutical and diagnostics sectors, offered to acquire 89bio, a clinical-stage biopharmaceutical company, in a $3.5bn deal. "We are thrilled to be joining with Roche to combine the promise of pegozafermin with Roche’s established global development, manufacturing, and commercialization capabilities, to accelerate and maximize potential benefit for patients in need and unlock significant shareholder value," Rohan Palekar, 89bio CEO.